AU1364701A - Methods to detect agents useful to inhibit neurofibromatosis type 1 (nf1) - Google Patents

Methods to detect agents useful to inhibit neurofibromatosis type 1 (nf1) Download PDF

Info

Publication number
AU1364701A
AU1364701A AU13647/01A AU1364701A AU1364701A AU 1364701 A AU1364701 A AU 1364701A AU 13647/01 A AU13647/01 A AU 13647/01A AU 1364701 A AU1364701 A AU 1364701A AU 1364701 A AU1364701 A AU 1364701A
Authority
AU
Australia
Prior art keywords
cells
nfl
kinase
scf
mast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13647/01A
Other languages
English (en)
Inventor
Wade D. Clapp
David A. Ingram
Mark Steven Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of AU1364701A publication Critical patent/AU1364701A/en
Assigned to ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. reassignment ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC., CLAPP, WADE D., INGRAM, DAVID A., MARSHALL, MARK STEVEN
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU13647/01A 1999-11-12 2000-11-10 Methods to detect agents useful to inhibit neurofibromatosis type 1 (nf1) Abandoned AU1364701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16521899P 1999-11-12 1999-11-12
US60165218 1999-11-12
PCT/US2000/030924 WO2001034201A2 (fr) 1999-11-12 2000-11-10 Methodes de detection d'agents utiles pour inhiber la neurofibromatose de type 1 (nf1)

Publications (1)

Publication Number Publication Date
AU1364701A true AU1364701A (en) 2001-06-06

Family

ID=22597961

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13647/01A Abandoned AU1364701A (en) 1999-11-12 2000-11-10 Methods to detect agents useful to inhibit neurofibromatosis type 1 (nf1)

Country Status (5)

Country Link
EP (1) EP1227846A2 (fr)
JP (1) JP2003513939A (fr)
AU (1) AU1364701A (fr)
CA (1) CA2388343A1 (fr)
WO (1) WO2001034201A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271067A1 (en) * 2000-07-19 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound
US7118854B2 (en) * 2001-03-30 2006-10-10 Rigel Pharmaceuticals, Inc. PAK2: modulators of lymphocyte activation
WO2012103165A2 (fr) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anticorps anti-kit et leurs utilisations
ES2415581B2 (es) * 2011-12-20 2014-02-19 Universidad Nacional De Educación A Distancia Compuestos potenciadores del aprendizaje.
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
JP6768639B2 (ja) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
JP6854766B2 (ja) 2015-01-26 2021-04-07 イエール ユニバーシティ チロシンキナーゼ阻害剤を用いる組成物および方法
US20220047567A1 (en) * 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007693A1 (fr) * 1997-07-11 2000-06-14 Merck & Co., Inc. (a New Jersey corp.) Genes et polypeptides de kinases pak, et leurs procedes d'utilisation
JP4596651B2 (ja) * 1999-04-02 2010-12-08 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション （ｅ）−スチリルスルホン抗癌剤

Also Published As

Publication number Publication date
EP1227846A2 (fr) 2002-08-07
WO2001034201A3 (fr) 2001-12-06
WO2001034201A9 (fr) 2002-07-25
WO2001034201A2 (fr) 2001-05-17
JP2003513939A (ja) 2003-04-15
CA2388343A1 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
Qin et al. Microglial TLR4-dependent autophagy induces ischemic white matter damage via STAT1/6 pathway
Mohan et al. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration
Cornelissen et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models
He et al. Erk1 positively regulates osteoclast differentiation and bone resorptive activity
Halder et al. Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis
Agassandian et al. VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis
Dasgupta et al. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes
de Vries et al. Tumor biology of vestibular schwannoma: a review of experimental data on the determinants of tumor genesis and growth characteristics
Oliveira et al. From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia
AU2008318656A1 (en) Biomarker for assessing response to FMS treatment
Xue et al. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
Zha et al. NLRC3 inhibits MCT‐induced pulmonary hypertension in rats via attenuating PI3K activation
AU1364701A (en) Methods to detect agents useful to inhibit neurofibromatosis type 1 (nf1)
Zhou et al. Alveolar type 2 epithelial cell senescence and radiation-induced pulmonary fibrosis
WO2007143629A1 (fr) Traitement de la neurofibromatose avec des inhibiteurs d'une voie de transduction du signal
WO2006111424A1 (fr) Procedes permettant d'identifier des modulateurs des recepteurs cannabinoides cb1 et cb2 et leur utilisation dans la cicatrisation des blessures
Wang et al. Pharmacological targeting of BET bromodomains inhibits lens fibrosis via downregulation of MYC expression
Bae et al. The crosstalk between MYC and mTORC1 during osteoclastogenesis
Chen et al. B cell lymphoma 10 is essential for FcεR-mediated degranulation and IL-6 production in mast cells
Yanda et al. The Mitochondrial Ca2+ import complex is altered in ADPKD
Chung et al. SOCS-1 is a central mediator of steroid-increased thymocyte apoptosis and decreased survival following sepsis
Warenius et al. Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity
Tsai et al. Tuberous sclerosis complex: genetic basis and management strategies
Wang et al. Loss of aquaporin 5 contributes to the corneal epithelial pathogenesis via Wnt/β‐catenin pathway
Rupert et al. IL-6 trans-signaling and crosstalk among tumor, muscle and fat mediate pancreatic cancer cachexia

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC.

Free format text: THE FORMER OWNER WAS: ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC., WADE D. CLAPP, DAVID A. INGRAM, MARK STEVEN MARSHALL